ADT Inc (ADT) Stock Price Today
Aura AI Summary
Key Stats
- $5.01BMARKET_CAP
- -VOLUME
- IndustrialsSECTOR
- $8.85FIFTY_TWO_WEEK_HIGH
- $6.30FIFTY_TWO_WEEK_LOW
- -TYPICAL_HOLD_TIME
- $12.56BENTERPRISE_VALUE
- 3.22%DIVIDEND_YIELD
- -TRADING_ACTIVITY
Track ADT Inc (ADT) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, ADT Inc has traded between a low of $6.3 and a high of $8.85, highlighting its annual price range. Buy and sell ADT Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About ADT Inc
ADT Inc is a provider of monitored security, interactive home and business automation, and related monitoring services in the United States and Canada. ADT offers residential, commercial, and multi-site customers a comprehensive set of burglary, video, access control, fire and smoke alarm, and medical alert solutions. It provides interactive home and business automation solutions designed to control access, react to movement, and sense carbon monoxide, flooding, changes in temperature or other environmental conditions, as well as address personal emergencies, such as injuries and medical emergencies. In addition, it offers professional monitoring of third-party devices through ADT Canopy platform. The product brands of the company are ADT and ADT Pulse, and Protection One brand.
Most Recent News
Global infant heart monitor market to reach $7.93B by 2035 with 10.85% CAGR, driven by tech advances and home care demand
The global infant heart monitor market, valued at $2.83 billion in 2025, is projected to grow to $7.93 billion by 2035 at a CAGR of 10.85%. Growth is fueled by advances in wearable and wireless monitoring technologies, increased adoption of home care...
Halper Sadeh LLC probes fairness of major company sales for shareholders' benefit.
Halper Sadeh LLC is investigating whether shareholders of Arcosa, Bio-Techne, Iridium Communications, and LCI Industries are receiving fair deals in their companies' recent sales. The law firm suspects insiders may gain financial benefits not availab...
Europe approves TEPKINLY combo for relapsed follicular lymphoma, offering a chemo-free treatment option.
The European Commission has approved TEPKINLY (epcoritamab) combined with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma in adults. This marks the first bispecific antibody-based therapy authorized in Europe for se...